Wellington Management Group LLP Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Wellington Management Group LLP lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 35,659,007 shares of the biopharmaceutical company’s stock after purchasing an additional 1,058,331 shares during the period. Gilead Sciences makes up approximately 0.6% of Wellington Management Group LLP’s holdings, making the stock its 29th largest holding. Wellington Management Group LLP’s holdings in Gilead Sciences were worth $3,293,822,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GILD. Southland Equity Partners LLC increased its holdings in shares of Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 110 shares during the period. Berkshire Bank grew its position in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 111 shares during the last quarter. CFO4Life Group LLC increased its stake in Gilead Sciences by 2.7% in the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 112 shares during the period. Howe & Rusling Inc. raised its position in Gilead Sciences by 2.5% during the 4th quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company’s stock worth $435,000 after buying an additional 115 shares during the last quarter. Finally, GHP Investment Advisors Inc. boosted its holdings in shares of Gilead Sciences by 1.1% in the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock valued at $1,049,000 after acquiring an additional 122 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 0.6 %

Gilead Sciences stock opened at $111.79 on Monday. The stock has a 50-day moving average price of $105.48 and a 200 day moving average price of $95.00. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The stock has a market cap of $139.22 billion, a PE ratio of 302.14, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were issued a $0.79 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.83%. Gilead Sciences’s payout ratio is 854.05%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on GILD shares. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday. Piper Sandler raised their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Finally, DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research note on Thursday, February 13th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $105.12.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.